Solnerstotug continues to be well tolerated, with no dose-limiting toxicities and the majority of AEs Grade 1 or 2 in severity. Out of 60 patients, there have been four (7%) cases of Grade 1 cytokine ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Zacks Investment Research on MSN11h
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New IndicationIntellia Therapeutics NTLA announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback